Inhibikase Therapeutics is a biotechnology business based in the US. Inhibikase Therapeutics shares (IKT.US) are listed on the NASDAQ and all prices are listed in US dollars. Its last market close was $1.39 – an increase of 3.73% over the previous day. Inhibikase Therapeutics employs 8 staff and has a trailing 12-month revenue of around $260,501.
Only you can make the decision on the time to leap... but here's some supporting information and analysis.
Over the last 12 months, Inhibikase Therapeutics's shares have ranged in value from as little as $0.79 up to $4.35. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inhibikase Therapeutics's is 1.199. This would suggest that Inhibikase Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Historical closes compared with the last close of $1.39
| 1 week (2024-04-25) | -18.71% |
|---|---|
| 1 month (2024-04-04) | -36.82% |
| 3 months (2024-02-04) | -45.49% |
| 6 months (2023-11-02) | 34.95% |
| 1 year (2023-05-04) | 114.70% |
| 2 years (2022-05-03) | 28.70% |
| 3 years (2021-05-04) | -74.12% |
The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Find out everything you need to know about technical analysis to help you become a better trader.
Technical analysis tells you a lot on a stock’s performance and can be a useful tool for your investing strategy, but isn’t a ready-made recipe for success.
A deep dive into the highlights and limitations of Frec.
Explore the best bonuses for opening a new brokerage account.
First impressions of financial planning platform Domain Money and how it compares to the competition.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
Our star ratings for online brokerages are based on how they stack up in nine key categories.
What you need to know about investing in the leading indicator for the overall US stock market.
The ins and outs of bundling stocks with this accessible investing option.